Mid-Day Breakouts Report - Wednesday, July 6th, 2022

<<<Previous Mid Day Report	Next Mid Day Report >>>
<<<Previous After Market Report	Next After Market Report >>>

You are not logged in.
This means you CAN ONLY VIEW reports that were published prior to Friday, February 16, 2024.
You MUST UPGRADE YOUR MEMBERSHIP if you want to see any current reports.

MIDDAY BREAKOUTS REPORT - WEDNESDAY, JULY 6TH, 2022
Previous Mid Day Report Next Mid Day Report >>>

DOW 30851.44 -116.38 (-0.38%) | NASDAQ 11259.54 -62.69 (-0.55%) | S&P 500 3812.52 -18.87 (-0.49%)

Time of Screening : 7/6/2022 12:00:49 PM Report Released : 7/6/2022 12:33:18 PM
Price is: Above 52W High and Less Than 52W High but within 15% of the 52 Week High
Volume Is: At least 40% of 50 Day Average at the time of the screening.
More details about this report...

To View Current Notes and Data on currently Featured Stocks go to the latest
Featured Stocks Page

Symbol/Exchange Company Name Industry Group	PRICE	CHANGE (%Change)	Day High	Volume (% DAV) (50 DAV)	52 Wk Hi % From Hi	Date Featured	Price Featured	Pivot Point
Symbol/Exchange Company Name Industry Group	PRICE	CHANGE (%Change)	Day High	Volume (% DAV) (50 DAV)	52 Wk Hi % From Hi	Date Featured	Price Featured	Max Buy
HRMY - NASDAQ Harmony Biosciences Holdings	$54.12	+1.47 2.79%	$55.16	485,504 94.83% of 50 DAV 50 DAV is 512,000	$54.00 0.22%	7/6/2022	$54.12	PP = $52.85 MB = $55.49
Most Recent Note - 7/6/2022 12:22:15 PM Y - Color code is changed to yellow with pivot point cited based on its 6/27/22 high. Hitting a new all-time high with today's gain. A gain and close above the pivot point backed by at least +40% above average volume may trigger a technical buy signal. Reported strong sales revenues and earnings increases in quarterly comparisons through Mar '22 versus the year ago periods. Annual earnings history is limited. Completed its $24 IPO on 8/19/20. There are no Featured Stock Updates™ available for this stock at this time. You may request one by clicking the Request a New Note link below
View all notes \| Alert me of new notes \| Company Profile \| SEC \| News \| Chart \| C A N S L I M
IMXI - NASDAQ International Money Express	$21.97	+0.04 0.18%	$22.45	264,818 71.19% of 50 DAV 50 DAV is 372,000	$22.86 -3.89%	7/1/2022	$21.27	PP = $21.38 MB = $22.45
Most Recent Note - 7/6/2022 12:26:40 PM Y - Perched within close striking distance of its 52-week high after recent volume-driven gains. Finished strong on 7/01/22 after highlighted in yellow with new pivot point cited based on its 6/06/22 high while building on a double bottom base. The gain and close above the pivot point was backed by +375% above average volume triggering a technical buy signal. Rebound above the 50 DMA line ($20) helped its outlook improve. Fundamentals through the Mar '22 quarter have been strong. Found support above its 200 DMA line since dropped from the Featured Stocks list on 5/20/22. >>> The latest Featured Stock Update with an annotated graph appeared on 7/1/2022. Click here.
View all notes \| Alert me of new notes \| Company Profile \| SEC \| News \| Chart \| C A N S L I M

Symbol - Exchange - Industry Group Company Name	Last	Chg	Day High	52 WK Hi	% From Hi	Volume % DAV	DAV
ALKS - NASDAQ - Medical-Biomed/Biotech Alkermes Plc	$30.97	-0.46 -1.46%	$32.13	$33.00	-6.15%	669,873 41.63%	1,609,000
Most Recent Note for ALKS - 7/6/2022 12:05:04 PM Reversed into the red after early gains today challenging its prior high and 52-week high. Prior mid-day report noted - "Reported earnings +9% on +11% sales revenues for the Mar '22 quarter versus the year ago period. Fundamental concerns remain. Earnings history is not a match with the fact-based investment system's guidelines."
View all notes \| Alert me of new notes \| Company Profile \| SEC \| News \| Chart \| C A N S L I M
ASH - NYSE - ENERGY - Oil & Gas Refining & Marketing Ashland Inc	$101.14	-0.46 -0.45%	$103.14	$112.91	-10.42%	188,474 45.42%	415,000
Most Recent Note for ASH - 7/6/2022 12:06:42 PM Consolidating near its 200 DMA line yet only -10.5% off its all-time high. Prior mid-day reports cautioned members - "Reported earnings +79% on +19% sales revenues for the Mar '22 quarter versus the year ago period. Annual earnings (A criteria) history is not a match with the fact-based investment system's guidelines."
View all notes \| Alert me of new notes \| Company Profile \| SEC \| News \| Chart \| C A N S L I M
AZN - NYSE - DRUGS - Drug Manufacturers - Major Astrazeneca Plc Ads	$65.82	+0.31 0.47%	$66.32	$71.70	-8.21%	3,772,421 52.76%	7,150,000
Most Recent Note for AZN - 7/6/2022 12:08:18 PM Consolidating above its 50 DMA line after finding support near its 200 DMA line. Prior mid-day reports noted - "Prior quarterly and annual earnings history is not a match with the fundamental guidelines of the fact-based investment system."
View all notes \| Alert me of new notes \| Company Profile \| SEC \| News \| Chart \| C A N S L I M
CORT - NASDAQ - DRUGS - Biotechnology Corcept Therapeutics Inc	$26.06	+0.33 1.28%	$26.68	$25.68	1.48%	552,391 64.23%	860,000
Most Recent Note for CORT - 7/6/2022 12:10:07 PM Hitting a new 52-week high with today's gain and little resistance remains due to overhead supply. Quarterly earnings increases through Mar '22 were not strong and steady above the +25% minimum guideline (C criteria). Annual earnings history (A criteria) had a downturn in FY '21.
View all notes \| Alert me of new notes \| Company Profile \| SEC \| News \| Chart \| C A N S L I M
FNKO - NASDAQ - Leisure-Toys/Games/Hobby Funko Inc Cl A	$24.08	-0.39 -1.59%	$25.20	$25.08	-3.99%	519,461 66.09%	786,000
Most Recent Note for FNKO - 7/6/2022 12:11:15 PM Challenging its May 2021 high with recent volume-driven gains. Quarterly comparisons through Mar '22 showed strong earnings increases (C criteria) with great sales revenues growth. Annual earnings (A criteria) history remains a concern after a big downturn in FY '20.
View all notes \| Alert me of new notes \| Company Profile \| SEC \| News \| Chart \| C A N S L I M
GIS - NYSE - FOOD & BEVERAGE - Food - Major Diversified General Mills Inc	$76.11	+0.96 1.28%	$76.47	$75.96	0.20%	2,218,870 56.62%	3,919,000
Most Recent Note for GIS - 7/6/2022 12:13:20 PM Perched at its all-time high after noted volume-driven gains, but prior mid-day reports cautioned members - "Sub par sales revenues increases and earnings versus year ago quarterly comparisons through May '22 versus the year ago period. Annual earnings growth has been slow and steady for this well-known name in the Food - Packaged industry group. Fundamentals fall short of the C and A criteria of the fact-based investment system."
View all notes \| Alert me of new notes \| Company Profile \| SEC \| News \| Chart \| C A N S L I M
GWW - NYSE - WHOLESALE - Electronics Wholesale Grainger W W Inc	$464.00	+8.83 1.94%	$464.21	$529.91	-12.44%	128,731 41.13%	313,000
Most Recent Note for GWW - 7/6/2022 12:16:59 PM Slumped below its 200 DMA line ($479) in recent weeks. Last noted with caution in the 4/14/22 mid-day report after wedging to new all-time highs with gains lacking great volume conviction. Reported earnings +58% on +18% sales revenues for the quarter ended March 31, 2022 versus the year ago period marking its 3rd consecutive quarterly comparison above the minimum +25% earnings guideline (C criteria). The annual earnings history for this Retail/Wholesale Building Products firm has been up and down which raises concerns with respect to the A criteria of the fact-based investment system's guidelines.
View all notes \| Alert me of new notes \| Company Profile \| SEC \| News \| Chart \| C A N S L I M
NL - NYSE - Hsehold/Office Furniture N L Industries	$9.05	-0.16 -1.68%	$9.20	$10.20	-11.32%	19,243 43.73%	44,000
Most Recent Note for NL - 7/6/2022 12:27:47 PM Pulled back from its 52-week high hit last week. Found support well above its 50 DMA line ($8.41) after rallying from a sound base pattern in recent weeks. Prior mid-day reports cautioned members - "Earnings and sales revenues history is below the fact-based investment system's guidelines."
View all notes \| Alert me of new notes \| Company Profile \| SEC \| News \| Chart \| C A N S L I M
NVO - NYSE - DRUGS - Drug Manufacturers - Other Novo Nordisk A/S Adr	$110.29	-0.95 -0.85%	$110.77	$122.16	-9.72%	708,022 46.98%	1,507,000
Most Recent Note for NVO - 7/6/2022 12:28:57 PM This Denmark-based Medical - Ethical Drug firm is consolidating near its 50 and finding support near its 200 DMA line. Prior mid-day reports repeatedly cautioned members - "Fundamental concerns remain after it reported Mar '22 quarterly earnings +8% on +17% sales revenues versus the year ago period."
View all notes \| Alert me of new notes \| Company Profile \| SEC \| News \| Chart \| C A N S L I M
OBCI - NASDAQ - CONSUMER NON-DURABLES - Cleaning Products Ocean Bio Chem Inc	$12.89	+0.01 0.08%	$12.90	$13.40	-3.81%	41,511 115.31%	36,000
Most Recent Note for OBCI - 7/6/2022 12:29:09 PM Gapped up on 6/22/22 following M&A news. Fundamental concerns remain. Noted with caution in prior mid-day reports - "Sales revenues growth and earnings history is not a match with the fact-based investment system's fundamental guidelines."
View all notes \| Alert me of new notes \| Company Profile \| SEC \| News \| Chart \| C A N S L I M
USAK - NASDAQ - TRANSPORTATION - Trucking U S A Truck Inc	$31.17	+0.13 0.42%	$31.17	$31.67	-1.58%	300,345 119.18%	252,000
Most Recent Note for USAK - 7/6/2022 12:29:35 PM Holding its ground after a gap up on 6/24/22 M&A news. Recent quarterly comparisons through Mar '22 were strong but its prior earnings history is not a match with the fundamental guidelines of the fact-based investment system.
View all notes \| Alert me of new notes \| Company Profile \| SEC \| News \| Chart \| C A N S L I M
VIVO - NASDAQ - DRUGS - Diagnostic Substances Meridian Bioscience Inc	$32.23	+0.88 2.80%	$32.44	$31.93	0.93%	1,100,843 255.42%	431,000
Most Recent Note for VIVO - 7/6/2022 12:31:01 PM Hitting another new 52-week high with today's volume-driven gain adding to a noted spurt of gains with heavy volume. Prior mid-day reports cautioned members - "Quarterly earnings increases through Mar '22 versus the year ago periods have been below the +25% minimum guideline (C criteria). Up and down annual earnings (A criteria) history is not a match with the fact-based investment system's fundamental guidelines. On 4/18/08 it was dropped from the Featured Stocks list."
View all notes \| Alert me of new notes \| Company Profile \| SEC \| News \| Chart \| C A N S L I M
VRTX - NASDAQ - Medical-Biomed/Biotech Vertex Pharmaceuticals	$291.07	+2.09 0.72%	$293.62	$293.17	-0.72%	755,635 42.14%	1,793,000
Most Recent Note for VRTX - 7/6/2022 12:33:09 PM Challenging prior highs with today's 5th consecutive gain. Rebounded above its 50 DMA line ($265) and the 6/23/22 mid-day report noted - "Reported earnings +18% on +22% sales revenues for the Mar '22 quarter versus the year-ago period, below the +25% minimum earnings guideline (C criteria). Annual earnings (A criteria) history has been strong."
View all notes \| Alert me of new notes \| Company Profile \| SEC \| News \| Chart \| C A N S L I M

THESE ARE NOT BUY RECOMMENDATIONS! Comments contained in the body of this report are technical opinions only. The material herein has been obtained from sources believed to be reliable and accurate, however, its accuracy and completeness cannot be guaranteed. We are not an investment advisor, hence it does not endorse or recommend any securities or other investments. Any recommendation contained in this report may not be suitable for all investors and it is not to be deemed an offer or solicitation on our part with respect to the purchase or sale of any securities. All trademarks, service marks and trade names appearing in this report are the property of their respective owners, and are likewise used for identification purposes only.

This report is a service available only to active Paid Premium Members. You may opt-out of receiving report notifications at any time. Questions or comments may be submitted by writing to FactBasedInvesting.com c/o Premium Member Services 665 S.E. 10 Street, Suite 201 Deerfield Beach, FL 33441-5634 or by calling 954-785-1121.

We appreciate any feedback members may wish to send via the inquiry form here.